Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling

JAMA Cardiol. 2017 Dec 1;2(12):1298-1299. doi: 10.1001/jamacardio.2017.3656.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticholesteremic Agents*
  • Cholesterol, LDL
  • Cost-Benefit Analysis
  • Humans
  • Proprotein Convertase 9*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9